We are live on ! Find out more
OPRX icon

OptimizeRx

98 hedge funds and large institutions have $180M invested in OptimizeRx in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 32 increasing their positions, 30 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

691% more call options, than puts

Call options by funds: $3.87M | Put options by funds: $489K

77% more capital invested

Capital invested by funds: $102M → $180M (+$78.1M)

40% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 15

4% more funds holding

Funds holding: 9498 (+4)

7% more repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 30

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

9.29% less ownership

Funds ownership: 78.55%69.26% (-9.3%)

Holders
98
Holders Change
+4
Holders Change %
+4.26%
% of All Funds
1.43%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
21
Increased
32
Reduced
30
Closed
15
Calls
$3.87M
Puts
$489K
Net Calls
+$3.38M
Net Calls Change
+$1.97M
Name Holding Trade Value Shares
Change
Change in
Stake
FLAM
1
First Light Asset Management
Minnesota
$24.7M -$7.28M -758,749 -31%
BlackRock
2
BlackRock
New York
$16.2M +$324K +33,804 +3%
Vanguard Group
3
Vanguard Group
Pennsylvania
$14.6M +$273K +28,416 +3%
DSCM
4
Divisadero Street Capital Management
Florida
$13.6M +$9.11M +949,550 New
AIC
5
AWM Investment Company
New York
$11.7M +$360K +37,471 +5%
William Blair & Company
6
William Blair & Company
Illinois
$10.6M -$915K -95,394 -11%
KCM
7
Kennedy Capital Management
Missouri
$7.02M -$624K -64,990 -12%
GIPM
8
G2 Investment Partners Management
New York
$6.7M +$927K +96,646 +26%
D.E. Shaw & Co
9
D.E. Shaw & Co
New York
$6.62M -$1.32M -137,886 -23%
SM
10
Samjo Management
New York
$5.88M +$3.94M +410,900 New
Geode Capital Management
11
Geode Capital Management
Massachusetts
$5.42M +$340K +35,417 +10%
RHJA
12
Rice Hall James & Associates
California
$4.9M -$428K -44,636 -12%
State Street
13
State Street
Massachusetts
$4.59M -$1.59M -165,259 -34%
CS
14
Credit Suisse
Switzerland
$4.54M +$4.06K +423 +0.1%
Dimensional Fund Advisors
15
Dimensional Fund Advisors
Texas
$3.67M -$67.4K -7,025 -3%
Federated Hermes
16
Federated Hermes
Pennsylvania
$2.62M -$1.58M -164,343 -47%
Northern Trust
17
Northern Trust
Illinois
$2.27M +$49.5K +5,162 +3%
Morgan Stanley
18
Morgan Stanley
New York
$2.23M +$1.04M +108,090 +226%
MAG
19
Millrace Asset Group
Pennsylvania
$1.92M +$1.29M +133,936 New
JP Morgan Chase
20
JP Morgan Chase
New York
$1.82M +$19.1K +1,993 +2%
BFM
21
Boothbay Fund Management
New York
$1.79M +$685K +71,399 +133%
BCM
22
Bridgeway Capital Management
Texas
$1.78M +$390K +40,600 +48%
BAM
23
Bullseye Asset Management
Colorado
$1.75M
Citadel Advisors
24
Citadel Advisors
Florida
$1.61M +$568K +59,206 +112%
Bank of New York Mellon
25
Bank of New York Mellon
New York
$1.52M +$11.7K +1,223 +1%

OPRX Hedge Fund Activity: Q4 2023 in Review

98 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in OptimizeRx (OPRX) for Q4 2023, worth a combined $180M — up 77% from $102M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new OPRX positions and 15 closed out — a net gain of 6 holders — while 32 added to existing stakes and 30 trimmed.

The largest buyer was Divisadero Street Capital Management, opening a new position worth an estimated $9.11M. The largest seller was First Light Asset Management, cutting an estimated $7.28M.

  • 98 institutional investors held OptimizeRx (OPRX) as of Q4 2023, up from 94 in Q3 2023.
  • Funds reported $180M of OptimizeRx stock for Q4 2023, up 77% quarter-over-quarter.
  • 21 funds opened new OptimizeRx positions in Q4 2023 and 15 closed out, a net change of +6 holders.
  • The largest OptimizeRx buyer in Q4 2023 was Divisadero Street Capital Management, an estimated $9.11M added.
  • The largest OptimizeRx seller in Q4 2023 was First Light Asset Management, an estimated $7.28M sold.

Based on aggregated 13F filings for Q4 2023.